Sign in
PTIXW Stock Price, Chart, Stats & News
Protagenic Therapeutics, Inc.
Save
Protagenic Therapeutics, Inc. (PTIXW) does not currently pay a dividend.
27,160
Market cap
–
Current P/E
–
Forward P/E
PTIXW chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -241.84% |
ROE | 184.88% |
D/E | -1.32x |
Interest coverage ratio | -21.36x |
PTIXW valuation
P/E | – |
P/S | – |
P/B | -0.42x |
P/CF | -0.24x |
P/FCF | -0.24x |
P/OCF | -0.24x |
PEG | -0.01x |
EV multiple | -0.01x |
About
Protagenic Therapeutics, Inc. is a biopharmaceutical company in its pre-clinical phase, dedicated to discovering and formulating treatments for neuropsychiatric and mood disorders that are related to stress. Its flagship compound, PT00114, is a laboratory-produced variant of teneurin carboxy-terminal associated peptide, a naturally occurring brain signaling peptide recognized for its capacity to moderate excessive stress reactions. The firm was established in 2016 and maintains its principal office in New York, New York.
Similar securities
Based on sector and market capitalization
Report issue